biostudies-literatureRudra SNIDDK NIH HHSNational Institute of Diabetes and Digestive and Kidney DiseasesNIH1408-1410.e2https://www.ebi.ac.uk/biostudies/studies/S-EPMC8792097biostudies-literatureUnknown20(6)Very early onset inflammatory bowel disease (VEO-IBD), diagnosed <6 years old, can be genetically and phenotypically distinct and more refractory than older-onset IBD. Identified causal monogenic defects have been targeted therapeutically in a small subset of VEO-IBD¹; however, for most of these children, treatment strategies, such as phenotypic profiles, are critically needed to improve outcomes.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationRuxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset Inflammatory Bowel Disease.PMC8792097R01 DK111843K23 DK119585R01 DK127044Shaul EPatel TDawany NSullivan KEMoore AConrad MBehrens ECanavan MCKelsen JRRudra SfalseRuxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset Inflammatory Bowel Disease.Very early onset inflammatory bowel disease (VEO-IBD), diagnosed <6 years old, can be genetically and phenotypically distinct and more refractory than older-onset IBD. Identified causal monogenic defects have been targeted therapeutically in a small subset of VEO-IBD¹; however, for most of these children, treatment strategies, such as phenotypic profiles, are critically needed to improve outcomes.2022-01-01T00:00:00Z2022 Jun2025-04-18T17:46:56.312Z2025-04-07T05:20:47.065ZS-EPMC87920973432977710.1016/j.cgh.2021.07.040